The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Alpha-synuclein Seed Amplification Assay Program, 2021Development of a Simplified, Rapid Method for Measuring Alpha-synuclein in Clinical Samples
Study Rationale: Alpha-synuclein aggregates are considered to be an excellent biomarker for the diagnosis of Parkinson’s disease (PD). The challenge is to optimize the tests currently used to detect...
-
Alpha-synuclein Seed Amplification Assay Program, 2021Detection of Single Molecules of Alpha-synuclein in Extracellular Vesicles
Study Rationale: The pathological changes observed in the brain tissue of people with Parkinson’s disease (PD) compared to healthy individuals motivated researchers to explore alpha-synuclein as a...
-
Alpha-synuclein Seed Amplification Assay Program, 2022Development of a Reliable Diagnostic Test for Parkinson’s Disease Using Patient Blood Samples
Study Rationale: Although diagnosis of Parkinson’s disease (PD) is crucial for the success of treatment, especially in the early stages, there are still no biomarkers available for use as a reliable...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Evaluation of “PDRepair,” a Novel Neuroprotective and Neurorestorative Therapeutic for GBA1-associated Parkinson’s Disease
Study Rationale: Mutations in the GBA1 gene, which encodes an enzyme called GCase, is the strongest genetic risk factor for Parkinson’s Disease (PD) and most often results in the production of GCase...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Efficacy and Biomarker Development for a Clinical Stage Inhibitor of Lipid Metabolism in Parkinson’s Disease
Study Rationale: A hallmark characteristic of Parkinson’s disease (PD) is the accumulation of alpha-synuclein, a small lipid-binding protein involved in transporting lipids and proteins throughout the...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Inhibiting Lrrk2 Specifically in the Brain
Study Rationale: Neurodegenerative disorders such as Parkinson’s disease (PD) affect the brain. Some of the drugs designed to treat PD have unwanted side effects in the rest of the body. To minimize...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.